Item 1(a). | Name of Issuer: |
enVVeno Medical Corporation (the “Issuer”)
Item 1(b). | Address of Issuer’s Principal Executive Offices: |
70 Doppler, Irvine, California 92618
Item 2(a). | Names of Persons Filing: |
The names of the persons filing this report (collectively, the “Reporting Persons”) are:
Perceptive Advisors LLC (“Perceptive Advisors”)
Joseph Edelman (“Mr. Edelman”)
Perceptive Life Sciences Master Fund, Ltd. (the “Master Fund”)
Item 2(b). | Address of Principal Business Office or, if None, Residence: |
The address of the principal business office of each of the Reporting Persons is:
51 Astor Place, 10th Floor
New York, NY 10003
Perceptive Advisors is a Delaware limited liability company
Mr. Edelman is a United States citizen
The Master Fund is a Cayman Islands corporation
Item 2(d). | Title of Class of Securities: |
Common Stock, $0.00001 par value per share (“Common Stock”)
29415J 106
Item 3. | If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: |
Not applicable.
The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover page to this Schedule 13G. The ownership percentages reported are based on 11,225,275 outstanding shares of Common Stock, as reported in the Issuer’s prospectus filed on September 8, 2021, giving effect to the full exercise of the pre-funded warrants issued by the Issuer, except for those pre-funded warrants that the Master Fund may not exercise pursuant to the terms of the pre-funded warrants it holds.